Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro

Leukemia

Volumn 28, Issue 12, 2014, Pages 2403-2406

  Sarkaria, S M ^a   Christopher, M J ^a   Klco, J M ^b   Ley, T J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD11B ANTIGEN; CD14 ANTIGEN; DIMETHYL SULFOXIDE; DNA METHYLTRANSFERASE 3A; EPZ 004777; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; ADENOSINE; CARBANILAMIDE DERIVATIVE; DOT1L PROTEIN, HUMAN; EPZ004777; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; METHYLTRANSFERASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; CELL DIFFERENTIATION; CONTROLLED STUDY; CRYOPRESERVATION; DNA METHYLATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; LEUKEMIA CELL LINE; PRIORITY JOURNAL; TREATMENT RESPONSE; ACUTE MYELOBLASTIC LEUKEMIA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; MUTATION;

ADENOSINE; CELL PROLIFERATION; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; METHYLTRANSFERASES; MUTATION; PHENYLUREA COMPOUNDS;

EID: 84926657869     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.235     Document Type: Letter

References (12)

1. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12: 599-612.
2. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
3. Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C et al. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia 2013; 27: 813-822.
4. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013; 122: 1017-1025.
5. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011; 20: 66-78.
6. Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood 2013; 121: 1633-1643.
7. Biswas D, Milne TA, Basrur V, Kim J, Elenitoba-Johnson KSJ, Allis CD et al. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc Natl Acad Sci USA 2011; 108: 15751-15756.
8. Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010; 37: 429-437.
9. Kuhn MWM, Hadler M, Daigle SR, Chen C, Sinha AU, Krivtsov AV et al. Myeloid leukemia cells With MLL partial tandem duplication are sensitive to pharmacological inhibition of the H3K79 methyltransferase DOT1L. Blood 2013; 122: 1256.
10. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483: 474-478.
11. Wang P, Dong Q, Zhang C, Kuan P-F, Liu Y, Jeck WR et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 2013; 32: 3091-3100.
12. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17-30.